VSTM
Verastem, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.62
−0.35%Oct 14, 2026, 13:46 UTC
Verastem, Inc. plans to raise $250 million.
Source:Oct 14, 2026, 10:13 UTC
Verastem said Daniel W. Paterson will retire as president and chief executive officer and Michael Bailey will become president and chief executive officer, effective January 1, 2027.
Source:Oct 14, 2026, 10:00 UTC
Verastem, Inc. reported clinical trial data showing VS-7375 activity in KRAS G12D-mutated cancers, including a 50% confirmed objective response rate in second-line pancreatic ductal adenocarcinoma and two complete responses in second-line-or-later disease, one confirmed.
Source:Sep 23, 2026, 00:06 UTC
GenFleet Therapeutics' overseas partner Verastem Oncology will hold an online investor call on October 14 to present overseas clinical development progress for GFH375/VS-7375.
Source:Aug 7, 2026, 00:00 UTC
Verastem, Inc. amended its Note Purchase Agreement on August 6, 2026, restructuring existing notes and adding a new series of up to $75 million in revenue-based notes.
Aug 6, 2026, 22:40 UTC
Verastem reported a second-quarter loss of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.46 and improving from a loss of $0.39 per share a year earlier.
Jun 17, 2026, 16:45 UTC
Verastem announced positive updated results from its RAMP 205 trial evaluating its drug combination for metastatic pancreatic cancer.
Source:Jun 3, 2026, 20:01 UTC
The U.S. FDA granted Fast Track Designation to Verastem Oncology's investigational drug VS-7375 for the treatment of KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer.